#United States #New York #Securities Fraud #Rosen Law Firm #MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Securities Fraud Class Action Opportunity

A recent announcement from the Rosen Law Firm, a premier global law firm focusing on investor rights, has reminded investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) of a significant opportunity to join a securities fraud class action lawsuit. This opportunity is directed specifically at those who purchased common stock of MoonLake between March 10, 2024, and September 29, 2025, the designated Class Period. The deadline for class members to file as lead plaintiff is December 15, 2025, a crucial date for affected investors.

The Importance of Joining the Lawsuit

If you were an investor during the Class Period, you could be eligible for compensation, which would come without any requirement for upfront fees. This arrangement is facilitated through a contingency fee model, meaning the firm only collects fees if they successfully recover funds for investors. Joining the lawsuit may provide a path to recover losses suffered due to alleged deceptive practices by MoonLake's leadership.

Steps to Participate

To participate in the ongoing class action, interested investors are encouraged to visit the Rosen Law Firm's website at rosenlegal.com. They can also reach out directly to Phillip Kim, Esq. at the law firm via a toll-free number, 866-767-3653, or by email at [email protected] for further assistance. Potential lead plaintiffs, who would take on a representative role in directing the litigation, must file their motions by the above-mentioned deadline.

Why Choose Rosen Law Firm?

The Rosen Law Firm is noted for its distinguished track record in handling securities class actions. Notably, the firm achieved the largest settlement against a Chinese company in securities class action history at one point and has been recognized for the number of successful class action settlements. Investors are advised to select experienced counsel in such matters, as many firms that issue notices may not possess comparable resources or experience in litigating securities cases, operating instead as intermediaries.

Context of the Case

The lawsuit is rooted in claims that during the Class Period, the defendants made misleading statements and failed to disclose important facts about their products. Central to the claims are alleged inaccuracies concerning the Nanobodies and monoclonal antibodies offered by the company. Specific allegations indicate that the firm’s claims regarding the advantages of their products—such as the supposed superiority of SLK over BIMZELX—were unfounded. The complaints suggest that when the truth was revealed to the market, investors faced financial harm due to these misrepresentations.

Stay Updated and Informed

For ongoing updates about the lawsuit and related issues, stakeholders are encouraged to follow the Rosen Law Firm on LinkedIn, Twitter, and Facebook. Those impacted should consider their options promptly, as participation in this class action could be pivotal in recovering financial losses incurred during the turbulent Class Period. It's imperative to consult with the firm or other legal advisors swiftly to understand your rights.

Legal Disclaimer

The information herein is provided for informational purposes only and constitutes attorney advertising. Previous results do not guarantee future outcomes. Investors contemplating participation in the lawsuit should review the specifics of their situation with qualified legal counsel. Until a class is certified, investors are not represented unless they actively choose to retain counsel. Remaining an absent class member is also an option, and participation decisions should be made carefully.

In conclusion, this notification serves as an essential reminder for MoonLake shareholders to evaluate their involvement and consider joining the class action for potential recovery of losses sustained during the Class Period.